ARTICLES BY ANNA ROSE WELCH

• The Marriage of Science & Strategy: Identifying mRNA Therapeutics' Value Propositions

  1/13/2025

  Though it’s not a question we can answer fully yet, in the first of this two-part article, CureVac CEO Alexander Zehnder starts us down the path of answering a critical question about our RNA therapies: In what ways can and should our mRNA products add value to our patients’ lives?

• Top 5 mRNA/RNA Advancements of 2024 (Part 2)

  12/30/2024

  As I took stock of the year behind us, there were five overarching ways in which I saw our industry taking steps forward and finding itself on sturdier scientific and clinical footing. Here, in the second of this two-part article, I continue down this list with my last three takeaways.

• Top 5 mRNA/RNA Developments of 2024 (Part 1)

  12/23/2024

  In the past few weeks, I’ve shared two articles outlining several RNA executives’ thoughts on advancements from 2024, as well as the challenges facing us in 2025. But why stop there? Below in the first of this two-part article, I share the first two of my five overarching observations from 2024.

• "The Ghost Of mRNA's Future": 2025 Outlook From RNA Leaders

  12/17/2024

  As the Charles Dickens fans among us already know, there is still one pretty important “ghost” that has yet to be channeled on this “hallowed” page, and that’s the “Ghost of mRNA/RNA Innovations Yet To Come.” (Yes. That’s a thing.) Here, I share several future-facing “visions” from the conversations I had with five RNA leaders.

• "Ghosts Of mRNA Past & Present": 6 RNA/LNP Execs Revisit 2024

  12/10/2024

  But much like Dicken's “A Christmas Carol” with its emphasis on how the past and present inform the future, I was struck by six RNA executive’s appreciation for where we have been and currently are as an industry, and how these moments in time are already informing mRNA/RNA’s bright future.

• Commercializing mRNA: 3 "Action Items" To Turn Promising Science Into Real-World Impact

  11/26/2024

  The recent Alliance for mRNA Medicines’ inaugural Ascent conference provided us with a lot of great updates on the mRNA industry’s progress. But throughout each of these specific conversations, there was a shared underlying question: How can we become a less esoteric industry?

• RNA Therapeutics: Navigating The "Holy Trinity" Of Structure, Process, & Biology

  11/19/2024

  During our hour-long conversation, Sagaert and I covered a lot of ground on the current state of the industry. But given his background in quality, it shouldn’t come as a surprise that our conversation ultimately gravitated back to some of the biggest questions we currently have and need to answer about our product’s structure and function — and how to adequately demonstrate this critical knowledge to regulators.

• Lessons From The Past: How mRNA Can Thrive In The Evolving ATMP Market

  11/4/2024

  Fortunately, as multiple presenters during the AGC CDMO Summit explained, there have been a few historical case studies of how the industries preceding us did (or didn’t quite) do the due-diligence they should have to trigger meaningful societal change. Not only do these case studies provide a few tactical pointers for those of us in the mRNA/RNA therapeutics space, I also think they can be particularly instructive in helping us craft/finetune mRNA’s value proposition.

• A Tale of Two Futures: Financial Trends Shaping The Advanced Therapies Space

  10/25/2024

  In the first of this two-part article, I’ll share a few of the commercial nuances informing what the path forward may look like for all of us in the ATMP financial sector.

• A "Flight Plan" For Achieving These 3 mRNA Development Milestones

  10/18/2024

  Here, in the final installment of this three-part series, I’ll share the panelists’ greatest learning experiences and regulatory advice (so far) on what we should be looking out for as we strive to achieve three big milestones: Entering the clinic; implementing advanced manufacturing technologies into our processes; and standardizing our manufacturing platforms.